BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 23551096)

  • 1. Achieving cancer cell death with PI3K/mTOR-targeted therapies.
    Yea SS; Fruman DA
    Ann N Y Acad Sci; 2013 Mar; 1280(1):15-8. PubMed ID: 23551096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
    Markman B; Dienstmann R; Tabernero J
    Oncotarget; 2010 Nov; 1(7):530-543. PubMed ID: 21317449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
    Pavlidou A; Vlahos NF
    ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
    Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
    Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
    Dienstmann R; Rodon J; Serra V; Tabernero J
    Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K-AKT-mTOR signaling network in cancer.
    Khan KH; Yap TA; Yan L; Cunningham D
    Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
    Yu L; Wei J; Liu P
    Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
    Lim HJ; Crowe P; Yang JL
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of mTOR Signaling as a Therapeutic Target in Cancer.
    Popova NV; Jücker M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
    LoRusso PM
    J Clin Oncol; 2016 Nov; 34(31):3803-3815. PubMed ID: 27621407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
    Zhu K; Wu Y; He P; Fan Y; Zhong X; Zheng H; Luo T
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PI3K/Akt/mTOR signaling by natural products.
    Huang S
    Anticancer Agents Med Chem; 2013 Sep; 13(7):967-70. PubMed ID: 23272914
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
    Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PI3K Signaling in Combination Cancer Therapy.
    Pons-Tostivint E; Thibault B; Guillermet-Guibert J
    Trends Cancer; 2017 Jun; 3(6):454-469. PubMed ID: 28718419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
    Singh P; Kumar V; Gupta SK; Kumari G; Verma M
    Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies.
    Mohite R; Doshi G
    Curr Cancer Drug Targets; 2024; 24(3):231-244. PubMed ID: 37526459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.